NCT05656131 2026-03-17
Fluzoparib in Combination With or Without Camrelizumab for Homologous Recombinant Deficiency (HRD) HER2 Negative Advanced Breast Cancer
Sun Yat-sen University
Phase 2 Suspended
Clinical Trials
8 trialsNCT07353437 2026-01-20
Fluzoparib as Adjuvant Treatment in Patients With Germline Homologous Recombination Repair (HRR) Mutated Primary Breast Cancer (Flamenco)
Fudan University
Phase 2 Not yet recruiting
NCT05594095 2024-10-04
SNF Platform Study of HR+/ HER2-advanced Breast Cancer
Fudan University
Phase 2 Recruiting
NCT06561022 2024-08-19
abemaSNF1/3
Fudan University
Phase 2 Not yet recruiting
NCT06254066 2024-02-12
Adebrelimab Combined With Fluzoparib in HRD-positive HR +/HER2- Advanced Breast Cancer
Zhejiang Cancer Hospital
Phase 2 Not yet recruiting
NCT05759546 2024-02-06
PARP Inhibitor With CDK4/6 Inhibitor and Endocrine Therapy in HR+/ HER2-Advanced Breast Cancer
Fudan University
Phase 2 Recruiting
NCT05761470 2023-03-09
IMPARP
First Affiliated Hospital, Sun Yat-Sen University
Phase 2 Recruiting
NCT04355858 2022-07-26
MULAN
Fudan University
Phase 2 Unknown